Following Countervail’s proposal response to a Biomedical Advanced Research and Development Authority (BARDA) solicitation for the development of a new neuroprotectant drug against nerve agents, a research and development contract was negotiated with options that when fully realized was valued at approximately $25M. In September 2011, the first award under that contract was granted of $5.3M to accomplish the base period scope of work.